This is a clinical trial to evaluate the safety and immunogenicity of R21/MM in healthy Kenyan participants from 3 different age groups. Participants will receive 3 vaccinations 4 weeks apart.
The study includes three age groups:
Group 1: healthy adults (18-45 years) Group 2: young children (aged 1-5 years) Group 3: infants (aged 5- <12 months of age) Each group will receive 3 vaccine doses which will be 4-weeks apart.
The trial is funded by The European & Developing Countries Clinical Trials Partnership (EDCTP), European Union